X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MRX-5 is a new type of benzodiazepine antibiotic used to treat infections caused by NTMs, non-tuberculosis mycobacteria refers to a large class of bacteria, excluding Mycobacteria tuberculosis, which causes chronic lung infections and results in lung damage.
Lead Product(s): Benzodiazepine
Therapeutic Area: Infections and Infectious Diseases Product Name: MRX-5
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The approval of contezolid from NMPA is based on the efficacy and safety result obtained from a multi-center, randomized, double-blind, double-dummy Phase III clinical trial involving 719 patients with complicated skin and soft tissue infections.
Lead Product(s): Contezolid
Therapeutic Area: Infections and Infectious Diseases Product Name: MRX-1
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The nondilutive financing is intended for a Phase 1 clinical trial and related R&D activities of its new antimicrobial agent MRX-8. Previously, CARB-X has funded investigational new drug (IND) enabling studies for MRX-8 in the US.
Lead Product(s): MRX-8
Therapeutic Area: Infections and Infectious Diseases Product Name: MRX-8
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
